Publications
Print PDF
Effects of GSK v Teva Ripple after SCOTUS Denies Cert
May 23, 2023
Chad Landmon, Ross Blau, and Gulrukh Haroon*
Life Sciences IP Review

Axinn partner Chad Landmon and associates Ross Blau and Gulrukh Haroon co-authored the Life Sciences IP Review article, "Effects of GSK v Teva Ripple after SCOTUS Denies Cert."

Click here to access the publication. A subscription is required. 

*Not yet admitted to the New York Bar

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.